Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

189.27USD
19 Oct 2017
Change (% chg)

$2.12 (+1.13%)
Prev Close
$187.15
Open
$185.00
Day's High
$190.57
Day's Low
$182.88
Volume
1,131,966
Avg. Vol
525,014
52-wk High
$256.78
52-wk Low
$182.88

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

8:59am IST

UPDATE 1-Native American tribe holding patents sues Amazon and Microsoft

Oct 18 A Native American tribe sued Amazon.com Inc and Microsoft Corp in federal court in Virginia on Wednesday for infringing supercomputer patents it is holding for a technology firm.

18 Oct 2017

Native American tribe holding patents sues Amazon and Microsoft

Oct 18 A Native American tribe sued Amazon.com Inc and Microsoft Corp in federal court in Virginia on Wednesday for infringing supercomputer patents it is holding for a technology firm.

18 Oct 2017

Allergan ruling casts doubt on tribal patent strategy

A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

18 Oct 2017

BRIEF-Neos therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

* Neos Therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

18 Oct 2017

Allergan ruling casts doubt on tribal patent strategy

A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

18 Oct 2017

BRIEF-Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​

* Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​

17 Oct 2017

BRIEF-Syndax Pharma enters into license agreement with unit of Allergan

* On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing

17 Oct 2017

BRIEF-‍Mylan invalidates Allergan's patents on Restasis​

* U.S. district court for Eastern District of Texas issued decision finding asserted claims of patents relating to Restasis invalid ​

17 Oct 2017

U.S. judge in Texas invalidates Allergan patents on Restasis

A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

17 Oct 2017

Earnings vs. Estimates